← Back to headlines
Turkish Cancer Drug Candidate RS-0139 Completes Phase 1 Clinical Trial
A new oncology drug candidate, RS-0139, originating from Türkiye, has successfully completed its Phase 1 clinical trial, marking a significant milestone in the country's biotechnology sector.
10 Apr, 12:08 — 10 Apr, 12:08
